Elizabeth Thiele, MD
Neurology with Special Qualifications in Child Neurology · Boston, MANPI 1982670535
Payments from drug & device makers
Across 294 payments — averaging $4791.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GW Research Limited$703K
- Jazz Pharmaceuticals Inc.$188K
- UCB, Inc.$126K
- UCB SA$97K
- Greenwich Biosciences, Inc.$84K
- Zogenix Inc.$79K
- plus $132K from 20 others
What the payments were for
- Consulting fees$219,59179%
- Speaking & faculty fees$29,91211%
- Travel & lodging$23,9979%
- Food & beverage$4,3232%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GW Research Limited | 29 | $702,531 |
| Jazz Pharmaceuticals Inc. | 64 | $187,903 |
| UCB, Inc. | 59 | $126,430 |
| UCB SA | 4 | $96,823 |
| Greenwich Biosciences, Inc. | 53 | $84,007 |
| Zogenix Inc. | 14 | $79,301 |
| GW Pharma Limited | 7 | $27,371 |
| H. Lundbeck A S | 3 | $21,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $19,499 |
| SK Life Science, Inc. | 6 | $14,005 |
| Neurelis, Inc. | 2 | $10,738 |
| Livanova USA, Inc. | 7 | $6,595 |
| Radius Health, Inc. | 4 | $6,365 |
| Biocodex, Inc. | 7 | $6,248 |
| Lundbeck LLC | 2 | $3,919 |
| BTG International Inc. | 4 | $2,941 |
| Eisai CO., LTD. | 1 | $2,400 |
| Aquestive Therapeutics, Inc. | 3 | $2,040 |
| Immedica Pharma US, Inc. | 2 | $1,909 |
| West Therapeutics Development, LLC | 2 | $1,750 |
| Eisai Inc. | 1 | $1,680 |
| Nobelpharma America, LLC | 1 | $1,290 |
| Azurity Pharmaceuticals, Inc. | 1 | $1,200 |
| Cadwell Industries, Inc | 1 | $66 |
| Merck | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$142,850
- Fintepla$23,083
- DIACOMIT$6,088
- VNS - Sentiva$4,587
- Fycompa$4,080
- Vimpat$3,526
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$2,008
- ZTALMY$1,909
- HYFTOR$1,290
- SYMPAZAN$1,020
How this compares
$1,408,558 in reported general payments places this provider in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 229 | $1,373,739 |
| Vigabatrin | 29 | $321,366 |
| FinteplaFenfluramine Hcl | 14 | $273,736 |
| XcopriCenobamate | 194 | $255,282 |
| Lamictal XrLamotrigine | 83 | $243,894 |
| OnfiClobazam | 44 | $159,324 |
| HyftorSirolimus | 36 | $144,166 |
| NayzilamMidazolam | 65 | $130,367 |
| KeppraLevetiracetam | 71 | $127,234 |
| TopamaxTopiramate | 13 | $80,925 |
| AptiomEslicarbazepine Acetate | 34 | $75,023 |
| VimpatLacosamide | 41 | $44,821 |
| Clobazam | 279 | $36,178 |
| NeurontinGabapentin | 13 | $34,947 |
| Depakote SprinkleDivalproex Sodium | 27 | $32,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Nayzilam, Vimpat | $126,430 | $448,924120 claims |
| SK Life Science, Inc.Xcopri | $14,005 | $255,282194 claims |
| Lundbeck LLCOnfi | $3,919 | $159,32444 claims |
| Nobelpharma America, LLCHyftor | $1,290 | $144,16636 claims |
| UCB SAKeppra | $96,823 | $127,23471 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $22 | $75,02334 claims |
| Neurelis, Inc.Valtoco | $10,738 | $22,89113 claims |
| Eisai Inc.Fycompa | $1,680 | $18,79915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
Other neurology with special qualifications in child neurology in Boston
- Basil DarrasBoston$8.4M
- Mustafa SahinBoston$8M
- David LiebermanBoston$935K
- Alexander RotenbergBoston$870K
- Kiran MaskiBoston$696K
- Leslie BensonBoston$467K
- Jurriaan PetersBoston$379K
- Tobias LoddenkemperBoston$365K
- Ann NeumeyerBoston$312K
- Phillip PearlBoston$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.